Ab&B Bio was founded in October 2015, with its inaugural project approved by China's NDRC (National Development and Reform Commission) the following month.

Ab&B Bio Takes Root in Fertile Ground!

In February 2016, an official agreement was signed with China Pharmaceutical City.

On May 1, 2016, the company successfully acquired the land plot through bidding, auction, and listing.

On September 1st, 2016, the groundbreaking ceremony for the project was held.

In December 2016, Ab&B Bio submitted the IND registration application for its Class 1 innovative biological product – a tetravalent influenza virus subunit vaccine.

Ab&B Bio is Working Hard!

In January 2017, the company signed an agreement for its new rabies vaccine project.

In February 2017, Ab&B Bio received the finished product qualification report for its tetravalent influenza virus subunit vaccine from the Chinese Academy of Inspection and Quarantine (CAIQ).

On August 1, 2017, the main structure of the facility was successfully topped out (construction milestone).

In November 2017, the company secured clinical trial approvals for its innovative Class 1 biological product, a tetravalent influenza virus subunit vaccine, in both pediatric and adult formulations.

In December 2017, the new rabies vaccine project officially commenced.

Ab&B Bio Dream Sets Sail!

In April 2018, the construction of the tetravalent influenza virus subunit vaccine stock solution and preparation workshop on Plot 1 was started.

In December 2018, the optimization and amplification of the tetravalent influenza virus subunit vaccine process and the preparation of phase I clinical samples were completed.

In December 2018, the A-round financing was successful, and Shenzhen Gaotejia Investment Group led the investment of 100 million yuan, boosting the launch of Zhonghui Biological Dream.

In December 2018, the plant construction was fully completed.

Ab&B Bio Goes Together!

In February 2019, the clinical protocol formulation and ethical committee approval of the tetravalent influenza virus subunit vaccine were completed.

In August 2019, the phase I clinical launch of the tetravalent influenza virus subunit vaccine was carried out.

In September 2019, workshop validation was completed, and process transfer, process amplification, and commercial batch production process validation were carried out.

In November 2019, the Phase I clinical field work of the tetravalent influenza virus subunit vaccine was completed.

In November 2019, the company obtained a drug production license.

In December 2019, the preparation of phase III clinical samples of the tetravalent influenza virus subunit vaccine was completed.

Ab&B Bio Creatures Seize Every Day!

In January 2020, the production process validation of commercial batches of tetravalent influenza virus subunit vaccine preparations was completed.

In May 2020, the joint application for the registration of the biological product class I new drug recombinant herpes zoster vaccine (CHO cell) project was successful.

In May 2020, the joint application for the biological product class I new drug nine-valent recombinant human papillomavirus vaccine (Pichia pastoris) project was successfully registered.

In May 2020, the phase III clinical trial of the tetravalent influenza virus subunit vaccine was launched.

On May 23, 2020, the contract for pneumococcal polysaccharide vaccine was successfully signed.

In July 2020, we obtained clinical approval documents for a new class of biological products, recombinant herpes zoster vaccine (CHO cell), and 9-valent recombinant human papillomavirus vaccine (Pichia pastoris).

In August 2020, the phase III clinical field work of the tetravalent influenza virus subunit vaccine was completed.

On September 23, 2020, the phase I clinical trial of pneumococcal polysaccharide vaccine was carried out.